Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Monday, September 30, 2024 1 min read
Key Takeaway: AbbVie Inc. has released updated guidance that incorporates the impact of acquired IPR D and milestones expense for the quarter ending September 30, 2024. The guidance suggests a slight decrease in adjusted diluted EPS range due to this expense, resulting in an EPS of $2.88 to $2.92 for the quarter. For the full year ending December 31, 2024, the adjusted diluted EPS range is projected to be between $10.67 and $10.87. However, the guidance does not account for any additional expenses that may occur beyond the third quarter, leading to some uncertainty.
Market Sentiment Analysis
POSITIVE FACTORS
Adjusted diluted EPS range for Q3 2024 remains positive.
Continued guidance for the full year indicates potential earnings stability.
CONCERNS & RISKS
Q3 guidance includes a notable expense impact from acquired IPR D.
There is uncertainty regarding additional milestones expenses beyond Q3 2024.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended September 30, 2024
Full-Year Ended December 31, 2024
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q3 2024 acquired IPR D and milestones expense
$
-
$
2.92
$
2.96
$
1,101
$
10.71
$
10.91
Q3 2024 acquired IPR D and milestones expense
82
(0.04)
(0.04)
82
(0.04)
(0.04)
Guidance including Q3 2024 acquired IPR D and milestones expense a
$
82
$
2.88
$
2.92
$
1,183
$
10.67
$
10.87
a The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the third quarter of 2024, as both cannot be reliably forecasted.
Frequently Asked Questions
What is the acquired IPR D expense for Q3 2024?
$82 million is the acquired IPR D expense for Q3 2024.
What is the adjusted diluted EPS range for full-year 2024?
The adjusted diluted EPS for full-year 2024 ranges from $10.67 to $10.87.
How does Q3 2024 impact adjusted diluted EPS?
Including Q3 2024 expenses, the adjusted EPS ranges from $2.88 to $2.92.
Is future IPR D expense forecasted for 2024?
No, future IPR D and milestone expenses beyond Q3 2024 cannot be reliably forecasted.
What was the previously announced EPS guidance?
The previously announced EPS guidance was between $2.92 and $2.96.